KZR-616
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Hemolytic Anemia
Conditions
Autoimmune Hemolytic Anemia, Immune Thrombocytopenia
Trial Timeline
Jul 1, 2020 → Aug 5, 2020
NCT ID
NCT04039477About KZR-616
KZR-616 is a phase 2 stage product being developed by Kezar Life Sciences for Autoimmune Hemolytic Anemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04039477. Target conditions include Autoimmune Hemolytic Anemia, Immune Thrombocytopenia.
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune Hemolytic Anemia were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04628936 | Phase 2 | Completed |
| NCT04039477 | Phase 2 | Withdrawn |
| NCT03393013 | Phase 1/2 | Completed |
Competing Products
20 competing products in Autoimmune Hemolytic Anemia